Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 17139406 | COMBINATION CONTAINING SGC STIMULATORS AND MINERALOCORTICOID RECEPTOR ANTAGONISTS | December 2020 | February 2023 | Allow | 25 | 1 | 0 | No | No |
| 17138356 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | December 2020 | March 2023 | Allow | 27 | 1 | 0 | No | No |
| 17136806 | OXO-SUBSTITUTED COMPOUND | December 2020 | February 2021 | Allow | 2 | 0 | 0 | No | No |
| 17131875 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) INFECTION | December 2020 | January 2022 | Allow | 12 | 2 | 0 | Yes | No |
| 17127966 | CYCLIZED SULFAMOYLARYLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | December 2020 | May 2023 | Abandon | 28 | 1 | 0 | No | No |
| 17252703 | SULFAMATE DERIVATIVES OF 4-(1-PHENYL-1H-[1,2,3]TRIAZOL-4-YL)-PHENOL, DERIVATIVES OF 4-(1-PHENYL-1H-[1,2,3]TRIAZOL-4-YL)-PHENOL, THEIR MEDICAL USE AND THE METHOD OF OBTAINING 4-(1-PHENYL-1H-[1,2,3]TRIAZOL-4-YL)-PHENYL SULFAMATE DERIVATIVES | December 2020 | November 2023 | Allow | 35 | 1 | 0 | No | No |
| 17108851 | INHIBITION OF COVID-19 VIRUS | December 2020 | November 2022 | Allow | 23 | 1 | 0 | No | No |
| 17101852 | SULFAMOYLBENZAMIDE DERIVATIVES AS ANTIVIRAL AGENTS AGAINST HBV INFECTION | November 2020 | May 2023 | Abandon | 29 | 0 | 1 | No | No |
| 17102341 | Methods for Cancer and Immunotherapy Using Prodrugs of Glutamine Analogs | November 2020 | April 2023 | Allow | 29 | 2 | 0 | No | No |
| 17057869 | Crystal Form Of Tenvermectin B, Preparation Method Therefor, And Use Thereof | November 2020 | October 2023 | Allow | 35 | 1 | 0 | No | No |
| 17099570 | ISOXAZOLINE PARASITICIDE FORMULATIONS AND METHODS FOR TREATING BLEPHARITIS | November 2020 | April 2023 | Abandon | 29 | 1 | 0 | No | No |
| 17096637 | BIPHENYL SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF KIDNEY DISEASES OR DISORDERS | November 2020 | April 2023 | Abandon | 29 | 1 | 0 | No | No |
| 17053817 | USE OF GUANABENZ OR DERIVATES THEREOF FOR THE TREATMENT OF TYPE I IFN-DEPENDENT PATHOLOGIES | November 2020 | June 2023 | Abandon | 31 | 2 | 0 | No | No |
| 17092058 | USE OF PYRONARIDINE, TILORONE, AND QUINACRINE AGAINST MARBURG VIRUS AND OTHER VIRUS INFECTIONS | November 2020 | February 2023 | Allow | 28 | 1 | 1 | No | No |
| 17087364 | OXYGENATED CHOLESTEROL SULFATES FOR THERAPY OF DISORDERS CAUSED BY AT LEAST ONE OF ATTENUATED LEPTIN ACTIVITY AND A LIPID STORAGE DISORDER | November 2020 | March 2023 | Abandon | 29 | 1 | 0 | No | No |
| 17080326 | METHODS OF OTOPROTECTION AGAINST PLATINUM-BASED ANTINEOPLASTIC AGENTS | October 2020 | February 2023 | Allow | 28 | 1 | 0 | No | No |
| 17074800 | METHOD OF INHIBITING MUTANT C-KIT | October 2020 | January 2023 | Allow | 27 | 1 | 0 | No | No |
| 17071637 | CURCUMINOID COMPOSITION FOR THERAPEUTIC MANAGEMENT OF METABOLIC SYNDROME | October 2020 | March 2023 | Allow | 29 | 2 | 0 | No | No |
| 17071740 | METHODS OF TREATING MULTIPLE SCLEROSIS | October 2020 | March 2021 | Allow | 5 | 1 | 0 | Yes | No |
| 17064693 | TREATMENT USING DANTROLENE | October 2020 | February 2023 | Abandon | 29 | 1 | 0 | No | No |
| 17061583 | COMBINATION FORMULATION CONTAINING COLCHICINE FOR TREATMENT OR ENHANCING THE THERAPY OF LIVER DISEASE | October 2020 | February 2023 | Allow | 28 | 2 | 0 | Yes | No |
| 17037932 | Use Of [(1R)-1-(2-Chlorophenyl)-2-(Tetrazol-2-YL)Ethyl] Carbamate In Combination Therapy | September 2020 | January 2023 | Allow | 27 | 1 | 0 | No | No |
| 17043978 | METHODS FOR TREATING HEPATITIS B VIRUS (HBV) INFECTION | September 2020 | July 2023 | Abandon | 33 | 2 | 0 | No | No |
| 17027617 | USE OF NEUTROPHIL ELASTASE INHIBITORS IN LIVER DISEASE | September 2020 | January 2023 | Abandon | 28 | 1 | 0 | No | No |
| 16981346 | ANTIVIRAL COMPOUNDS AND USE THEREOF | September 2020 | July 2023 | Allow | 34 | 2 | 1 | No | No |
| 16981325 | ANTIVIRAL PRODRUGS AND FORMULATIONS THEREOF | September 2020 | May 2022 | Allow | 20 | 1 | 0 | No | No |
| 17009881 | Broad Spectrum Antiviral and Methods of Use | September 2020 | December 2022 | Abandon | 27 | 1 | 0 | No | No |
| 16977309 | INHIBITION OF NSMASE FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS INFECTION | September 2020 | May 2023 | Allow | 32 | 1 | 1 | No | No |
| 17008352 | The Pharmaceutical Composition Intended to Inhibit HIV Infectivity in Order to Treat the Acquired Immune Deficiency Syndrome (AIDS) and Its Complications | August 2020 | April 2023 | Abandon | 32 | 2 | 0 | No | No |
| 17006169 | METHOD FOR INHIBITING CORONAVIRUS INFECTION AND REPLICATION | August 2020 | May 2023 | Abandon | 32 | 2 | 0 | No | No |
| 17006103 | METHOD FOR INHIBITING CORONAVIRUS INFECTION AND REPLICATION | August 2020 | March 2023 | Abandon | 31 | 2 | 0 | No | No |
| 17003297 | Method of Administering Sotalol IV/SWITCH | August 2020 | October 2022 | Allow | 26 | 2 | 0 | No | No |
| 16997447 | Treatment Of Adipocytes | August 2020 | August 2022 | Allow | 24 | 2 | 0 | Yes | No |
| 16970543 | Treatment Of Liver Diseases | August 2020 | November 2023 | Abandon | 39 | 4 | 0 | No | No |
| 16995594 | NOVEL REVERSIBLE NITROXIDE DERIVATIVES OF NITROALKENES THAT MEDIATE NITROSATING AND ALKYLATING REACTIONS | August 2020 | July 2022 | Allow | 23 | 1 | 0 | No | No |
| 16988239 | METHODS FOR IMPROVED PROTECTION AND DELIVERY OF AMINOTHIOLS AND ANALOGS THEREOF | August 2020 | September 2022 | Allow | 25 | 1 | 0 | No | No |
| 16967752 | USE OF MODULATORS OF NEET PROTEINS FOR THE TREATMENT OF INFECTION | August 2020 | January 2023 | Abandon | 29 | 1 | 2 | No | No |
| 16986200 | BIPHENYL-CONTAINING DIARYLPYRIMIDO COMPOUNDS, PHARMACEUTICALLY-ACCEPTABLE SALTS THEREOF, COMPOSITION AND PREPARATION THEREOF | August 2020 | May 2022 | Allow | 21 | 1 | 0 | No | No |
| 16984384 | METHODS AND COMPOSITIONS FOR TREATMENT OF PAIN USING CAPSAICIN | August 2020 | April 2021 | Allow | 8 | 1 | 0 | No | No |
| 16983955 | USE OF PANTOPRAZOLE IN PREVENTION AND TREATMENT OF NONALCOHOLIC FATTY LIVER DISEASE | August 2020 | January 2023 | Abandon | 29 | 2 | 0 | No | No |
| 16983492 | USES OF OXYGENATED CHOLESTEROL SULFATES (OCS) | August 2020 | May 2022 | Allow | 21 | 1 | 0 | Yes | No |
| 16938228 | COMPOSITIONS AND METHODS FOR TREATING AN INFECTION | July 2020 | October 2022 | Allow | 27 | 1 | 1 | Yes | No |
| 16937263 | REVERSIBLY PROTECTED THIOLATED ELECTROPHILIC FATTY ACIDS AS PRODRUGS | July 2020 | February 2023 | Allow | 31 | 2 | 1 | Yes | No |
| 16921610 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS | July 2020 | May 2022 | Allow | 22 | 1 | 0 | No | No |
| 16919404 | TREATMENT FOR PRIMARY BILIARY CHOLANGITIS | July 2020 | April 2022 | Abandon | 22 | 1 | 0 | No | No |
| 16636752 | Therapeutic Agent for Fatty Liver Diseases and Therapeutic Agent for Adiposity | June 2020 | March 2021 | Allow | 13 | 1 | 0 | No | No |
| 16914276 | COMBINATION FORMULATION CONTAINING COLCHICINE FOR TREATMENT OR ENHANCING THE THERAPY OF LIVER DISEASE | June 2020 | June 2022 | Abandon | 24 | 1 | 0 | No | No |
| 16911932 | METHODS AND MATERIALS FOR TREATING POLYCYSTIC KIDNEY DISEASE | June 2020 | June 2022 | Abandon | 24 | 1 | 0 | No | No |
| 16958053 | ASK1 INHIBITOR COMPOUNDS AND USES THEREOF | June 2020 | March 2022 | Allow | 20 | 1 | 0 | Yes | No |
| 16955482 | ANTIVIRAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR | June 2020 | May 2022 | Allow | 23 | 1 | 1 | No | No |
| 16904262 | Uridine Phosphorylase (UPase) Inhibitors for Treatment of Liver Conditions | June 2020 | June 2022 | Allow | 23 | 2 | 0 | Yes | No |
| 16954824 | NOVEL ANTIVIRAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR | June 2020 | February 2022 | Allow | 20 | 1 | 0 | No | No |
| 16899587 | METHOD FOR PREVENTING OR TREATING NON-ALCOHOLIC FATTY LIVER DISEASE BY ANTRODINS | June 2020 | August 2022 | Allow | 26 | 2 | 0 | No | No |
| 16771877 | RENAL DYSFUNCTION IMPROVING DRUG COMPRISING OPTICAL ISOMER OF 1,4-BENZOTHIAZEPINE-1-OXIDE DERIVATIVE | June 2020 | August 2023 | Allow | 38 | 3 | 0 | No | No |
| 16896443 | Pharmaceutical Composition For Treating Obesity Induced By High Fat Diet And Non-Alcoholic Fatty Liver Disease By Using Trisodium Chlorin E6 Photosensitizer | June 2020 | August 2022 | Abandon | 26 | 1 | 0 | No | No |
| 16894407 | PEPTIDOMIMETICS FOR THE TREATMENT OF CORONAVIRUS AND PICORNAVIRUS INFECTIONS | June 2020 | August 2021 | Allow | 14 | 1 | 1 | No | No |
| 16770014 | TREATMENT OF RSV WITH COMBINATION PRODUCT | June 2020 | February 2022 | Allow | 21 | 1 | 0 | Yes | No |
| 15733145 | CORROLES FOR TREATING HUMAN CYTOMEGALOVIRUS INFECTIONS | May 2020 | April 2022 | Allow | 22 | 1 | 0 | No | No |
| 16768049 | PYRAZOLOPYRIMIDINES HAVING ACTIVITY AGAINST THE RESPIRATORY SYNCYTIAL VIRUS (RSV) | May 2020 | January 2022 | Allow | 20 | 1 | 0 | No | No |
| 16767881 | USING PROBENECID TO TREAT POLYCYSTIC KIDNEY DISEASE | May 2020 | August 2022 | Allow | 27 | 2 | 0 | No | No |
| 16767280 | COMPOSITIONS AND METHODS FOR TREATING ACUTE MYELOID LEUKEMIA | May 2020 | March 2023 | Abandon | 33 | 0 | 1 | No | No |
| 16767078 | FXR AGONISTS FOR THE TREATMENT OF LIVER DISEASES | May 2020 | November 2022 | Abandon | 30 | 1 | 0 | No | No |
| 16882206 | BIPHENYL SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF KIDNEY DISEASES OR DISORDERS | May 2020 | November 2020 | Allow | 5 | 1 | 0 | No | No |
| 16765365 | NEW METHOD FOR TREATING DENGUE VIRUS INFECTION | May 2020 | July 2023 | Allow | 38 | 4 | 1 | No | No |
| 16765307 | PREVENTION AND TREATMENT OF VIRAL INFECTIONS | May 2020 | March 2022 | Allow | 22 | 2 | 0 | Yes | No |
| 16874617 | SEMIFLUORINATED COMPOUNDS AND THEIR COMPOSITIONS | May 2020 | January 2022 | Allow | 21 | 2 | 0 | Yes | No |
| 16869672 | TREATMENT OF SCHIZOPHRENIA USING BETA-CARYOPHYLLENE AND CB2 RECEPTOR AGONISTS | May 2020 | November 2022 | Allow | 30 | 3 | 0 | Yes | No |
| 16862500 | COMPOSITIONS AND METHODS FOR MITIGATING AFLATOXIN B1-INDUCED LIVER INJURY | April 2020 | March 2022 | Allow | 22 | 1 | 0 | No | No |
| 16858447 | NICOTINAMIDE MONONUCLEOTIDE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF VIRAL INFECTIONS | April 2020 | January 2023 | Abandon | 33 | 2 | 0 | No | No |
| 16854355 | SUBSTITUTED BISPHENYL BUTANOIC ESTER DERIVATIVES AS NEP INHIBITORS | April 2020 | November 2021 | Allow | 18 | 1 | 0 | No | No |
| 16756720 | NOVEL MEK-INHIBITOR FOR THE TREATMENT OF VIRAL AND BACTERIAL INFECTIONS | April 2020 | October 2023 | Allow | 42 | 3 | 0 | Yes | No |
| 16847516 | USES OF INDOLINONE COMPOUNDS | April 2020 | November 2021 | Allow | 19 | 2 | 0 | Yes | No |
| 16844198 | COMPOUNDS FOR THE TREATMENT OF CANCERS ASSOCIATED WITH HUMAN PAPILLOMAVIRUS | April 2020 | June 2021 | Allow | 15 | 1 | 0 | No | No |
| 16843832 | DIRECTED DIFFERENTIATION OF OLIGODENDROCYTE PRECURSOR CELLS TO A MYELINATING CELL FATE | April 2020 | October 2021 | Allow | 18 | 2 | 0 | Yes | No |
| 16754220 | DIHYDROPYRIMIDINE COMPOUNDS AND USES THEREOF IN MEDICINE | April 2020 | December 2021 | Allow | 20 | 1 | 0 | Yes | No |
| 16753814 | Enantiomers Of Substituted Thiazoles As Antiviral Compounds | April 2020 | December 2021 | Allow | 20 | 1 | 0 | Yes | No |
| 16840359 | 5-SUBSTITUTED 2,4-THIAZOLIDINEDIONES (THIOHYDANTOINS), PSEUDOTHIOHYDANTOINS, AND PROPSEUDOTHIOHYDANTOINS FOR USE AS ANTIVIRAL AGENTS | April 2020 | September 2021 | Allow | 17 | 1 | 1 | Yes | No |
| 16835905 | METHOD OF TREATING AND PREVENTING CORONAVIRUSES WITH LOW DOSAGE INTERFERON BETA-1A AS A TH17 INHIBITOR | March 2020 | December 2022 | Abandon | 32 | 1 | 0 | No | No |
| 16835733 | ANTIVIRAL THERAPY | March 2020 | March 2021 | Allow | 12 | 1 | 0 | Yes | No |
| 16652044 | Use of Nor-Ursodeoxycholic Acid for Reducing Liver Fat | March 2020 | October 2023 | Allow | 42 | 5 | 0 | Yes | No |
| 16651470 | USE OF SENOLYTIC AGENTS TO ELIMINATE PERSISTENT HIV RESERVOIRS | March 2020 | July 2022 | Abandon | 27 | 1 | 1 | No | No |
| 16828727 | HIGH CONCENTRATION FORMULATION | March 2020 | August 2021 | Allow | 17 | 2 | 0 | No | No |
| 16825263 | TREATING INFLUENZA USING SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES AND PRODRUGS THEREOF IN A SUBJECT HAVING INFLUENZA AND A SEVERE INFLUENZA CONDITION | March 2020 | October 2022 | Abandon | 31 | 2 | 0 | Yes | No |
| 16823250 | KITS, COMPOSITIONS AND METHODS FOR WOUND TREATMENT AND MANAGEMENT | March 2020 | May 2021 | Abandon | 14 | 1 | 0 | No | No |
| 16821290 | BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | March 2020 | October 2021 | Allow | 19 | 1 | 0 | No | No |
| 16816014 | USE OF GLUCOCORTICOID RECEPTOR ANTAGONISTS IN COMBINATION WITH GLUCOCORTICOIDS TO TREAT ADRENAL INSUFFICIENCY | March 2020 | October 2021 | Allow | 19 | 2 | 1 | Yes | No |
| 16814669 | TREATING INFLUENZA USING SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES AND PRODRUGS THEREOF IN A SUBJECT HAVING INFLUENZA AND A COMPLICATION RISK FACTOR | March 2020 | March 2023 | Abandon | 36 | 3 | 0 | Yes | No |
| 16645704 | COMBINATIONS COMPRISING FXR AGONISTS | March 2020 | March 2023 | Abandon | 36 | 2 | 0 | No | Yes |
| 16807970 | REDUCING THE RISK OF VIRAL INFECTION DUE TO VIRAL CONTAMINATED FEED | March 2020 | September 2022 | Allow | 31 | 2 | 0 | No | No |
| 16808089 | PRE-EXPOSURE PROPHYLAXIS OF HIV INFECTIONS | March 2020 | November 2020 | Allow | 8 | 1 | 0 | No | No |
| 16808135 | METHODS OF INHIBITING HIV INFECTIONS BY PRE-EXPOSURE PROPHYLAXIS | March 2020 | November 2020 | Allow | 9 | 1 | 0 | No | No |
| 16808120 | METHODS OF PREVENTING HIV INFECTIONS IN HUMANS | March 2020 | November 2020 | Allow | 9 | 1 | 0 | No | No |
| 16642905 | NOVEL USES OF PIPERIDINYL-INDOLE DERIVATIVES | February 2020 | October 2021 | Allow | 20 | 1 | 0 | No | No |
| 16800209 | METHOD AND COMPOSITION FOR INHIBITING VIRUS INFECTION | February 2020 | November 2021 | Allow | 21 | 1 | 0 | No | No |
| 16490546 | MAP KINASE PATHWAY TARGETS FOR THE TREATMENT OF MARFAN SYNDROME | February 2020 | February 2023 | Allow | 41 | 2 | 1 | Yes | Yes |
| 16794775 | MIXTURES OF SABADILLA ALKALOIDS AND PYRETHRUM AND USES THEREOF | February 2020 | March 2022 | Allow | 25 | 4 | 0 | Yes | No |
| 16793441 | DIACYLGLYCEROL ACYL TRANSFERASE 2 INHIBITORS | February 2020 | February 2021 | Allow | 12 | 1 | 0 | No | No |
| 16788454 | MIXTURES OF SABADILLA ALKALOIDS AND AZADIRACHTIN AND USES THEREOF | February 2020 | November 2021 | Allow | 21 | 2 | 0 | No | No |
| 16636477 | COMBINATIONS AND USES AND TREATMENTS THEREOF | February 2020 | April 2022 | Abandon | 27 | 2 | 0 | No | No |
| 16636452 | COMBINATIONS AND USES AND TREATMENTS | February 2020 | April 2022 | Abandon | 27 | 2 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner WANG, SHENGJUN.
With a 27.7% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 17.9% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner WANG, SHENGJUN works in Art Unit 1627 and has examined 1,370 patent applications in our dataset. With an allowance rate of 52.5%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 33 months.
Examiner WANG, SHENGJUN's allowance rate of 52.5% places them in the 15% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by WANG, SHENGJUN receive 2.07 office actions before reaching final disposition. This places the examiner in the 51% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by WANG, SHENGJUN is 33 months. This places the examiner in the 45% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +37.3% benefit to allowance rate for applications examined by WANG, SHENGJUN. This interview benefit is in the 84% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 21.2% of applications are subsequently allowed. This success rate is in the 27% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 44.0% of cases where such amendments are filed. This entry rate is in the 68% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 65.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 53% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 62.1% of appeals filed. This is in the 40% percentile among all examiners. Of these withdrawals, 66.2% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.
When applicants file petitions regarding this examiner's actions, 59.0% are granted (fully or in part). This grant rate is in the 60% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 2.8% of allowed cases (in the 79% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 3.1% of allowed cases (in the 76% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.